The University of Michigan Comprehensive Cancer Center (UWCCC) requests renewal of its core grant in support of senior leadership, programs and shared core facilities. A core grant to support the UMCCC was initially awarded by NCI in 1988 and renewed for five years in 1991 and 1995. The Cancer Center received comprehensive designation in 1991. The Center provides an organizational framework to promote inter- disciplinary research through the development of defined clinical, basic and prevention programs in cancer research, and the development and support of shared resources. The Cancer Center has experienced considerable growth over the current grant period with a 76% increase in NCI funding and a doubling of patient accruals to clinical therapeutic trials. In 1997 the Center moved to a new $88 million facility which houses the Center's outpatient clinics and four and one half floors of research laboratories. The Cancer Center's four basic research programs are: Cancer Genetics/Virology, Cancer Cell Biology, Tumor Immunology and, Experimental Therapeutics. The eight clinical research programs investigating the biology and therapeutics of disease sites are: Cancer Genetics/Virology, Cancer Cell Biology, Tumor Immunology, and Experimental Therapeutics. The eight clinical research programs investigating the biology and therapeutics of disease sites are: Breast, Prostrate, Leukemia/Lymphoma, GI, Cutaneous, Childhood Cancers, Head & Neck, and Connective Tissue. The two prevention programs are Biomedical and Socio-Behavioral. Support is requested for a total of 13 shared core facilities: 11 9ongoing in Clinical Trials, Biostatistics, Tissue Procurement, Tumor Imaging, DNA and Protein Analysis, Morphology Flow Cytometry, Experimental Radiation, Animal Facility, Transgenic Mouse and Vector cores, as well as two new cores in DNA Array Analysis and Immune Monitoring. The Cancer Center senior leadership is composed of the director and five associate directors. Funds are also requested for Development, Planning and Evaluation, and Administration to support Center goals. Over the past 10 years the University and Medical Center have made substantial commitments to the Cancer Center, totaling over $130 million. The UMCCC members receive nearly $66 million in research funding, including over $20 million in annual direct NCI support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-16
Application #
6633000
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1988-09-30
Project End
2006-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
16
Fiscal Year
2003
Total Cost
$5,055,037
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224
Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224
Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458
Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865

Showing the most recent 10 out of 1493 publications